ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2467

Validation of the FLARE Questionnaire for the Detection of a Disease Flare in Rheumatoid Arthritis

Ana Lizarraga1, Margarita Landi2, Emilce Schneeberger2, Josefina Gallino Yanzi3, Graciela Betancur1, Cecilia Zaffarana2, Maria Celeste Orozco4, Osvaldo Luis Cerda5, Fernando Dal Pra3 and Gustavo Citera2, 1Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 4Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 5IREP, CABA, Argentina

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: questionnaires and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  Patients with Rheumatoid Arthritis (RA) commonly suffer disease flares. The FLARE questionnaire was developed in order to detect the presence of a flare within the 3 months previous to the medical visit. The objective of our study was to validate the FLARE questionnaire into the Spanish language and to estimate the cut-off value for defining a disease flare.

Methods:  Patients with RA according to ACR/EULAR 2010 criteria, ≥ 18 years of age were included. Sociodemographic and disease characteristics were recorded. Patients attended a baseline visit and thereafter every 3 months. Disease activity (28 joints count, ESR, CRP, DAS28) and functional status (HAQ) were assessed at each visit. Baseline treatment was recorded and at each follow-up visit a treatment change was analysed. FLARE was translated into Spanish and cultural adapted. Patients completed the FLARE questionnaire, consisting of 13 statements that are answered on a 6/Likert scale. The final scores results of the addition of the 13 questions, with a final results range between 13 and 78; 13 representing the highest probability of having suffered a disease flare. Both patients and physicians had to answer if they considered having suffered a disease flare. Between each visit, patients completed a RAPID-3 questionnaire weekly. A disease flare was defined as an increase in DAS28 ≥ 1.2 or ≥ 0.6 if the previous DA28 was ≥3.2, a difference in RAPID-3 > 3.6 between each visit or a significant treatment change.

Results:  105 patients were included, 84.8% were women, with a median age of 44 years (IQR 34 to 54.7), median disease duration of 20.5 months (IQR 6 to 45.7 months). Patients were evaluated over 6 consecutive visits, however due to a lost to follow-up of more than 50%, only the first 3 visits were analyzed. The treatment change frequency at each visit was: N°1= 54/101 (53.5%), N°2= 31/57 (54.4%) and N°3= 16/33 (48.5%). And the types of treatment change frequency were: Steroid increase (43.8%), DMARDs increase (26.6%), DMARDs combination (8.3%), biologic therapy addition (16.3%), intraarticular steroid injection 41%. Association between mean FLARE values and changes in disease activity is shown in Table 1. In the ROC curve analysis a FLARE cut-off value of 50.5 showed a sensitivity and specificity greater than 60.

Conclusion:  The FLARE questionnaire is a valid and simple to use instrument for detecting a disease flare in RA patients. A cut-off value ≤ a 50.5 determines the presence of a disease flare within the 3 months previous to the medical visit. Table 1. Comparison between the FLARE questionnaire and other definitions of disease flare

Flare according to RAPID (increase > 3.6 between 2 visits)

YES

NO

p

FLARE X (SD)

44 (±27.5)

51.3 (±22.1)

0.61

Flare according to DAS28 increase between visit 1 and 2

YES

NO

p

FLARE X (SD)

43.7 (±23.1)

54.7 (±18.7)

0.17

Flare according to physician´s opinion

YES

NO

p

FLARE X (SD)

43.6 (±15.9)

51.1 (±18.1)

0.24

Flare according to patient´s opinion

YES

NO

p

FLARE X (SD)

34.1 (±10.4)

57.2 (±15.4)

0.0001

Flare according to treatment change between visits

YES

NO

p

FLARE 1 X (SD)

46.1 (±16.4)

54.8 (±17.9)

0.012

FLARE 2 X (SD)

44.1 (±20.2)

61.1 (±14.9)

0.002

FLARE 3 X (SD)

36 (±16.4)

59.1 (±18.8)

0.003


Disclosure: A. Lizarraga, None; M. Landi, None; E. Schneeberger, None; J. Gallino Yanzi, None; G. Betancur, None; C. Zaffarana, None; M. C. Orozco, None; O. L. Cerda, None; F. Dal Pra, None; G. Citera, None.

To cite this abstract in AMA style:

Lizarraga A, Landi M, Schneeberger E, Gallino Yanzi J, Betancur G, Zaffarana C, Orozco MC, Cerda OL, Dal Pra F, Citera G. Validation of the FLARE Questionnaire for the Detection of a Disease Flare in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/validation-of-the-flare-questionnaire-for-the-detection-of-a-disease-flare-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validation-of-the-flare-questionnaire-for-the-detection-of-a-disease-flare-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology